Intranasal administration of Mycoplasma hyopneumoniae antigen
US5240706A · kind A · utility
18Cited by
2References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 7, 1989 |
| Grant date | Aug 31, 1993 |
| Priority date | — |
| Expiry date | Apr 7, 2009 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/821
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for protecting an animal, in particular swine, against mycoplasma pneumonia by administering intranasally to the animal a vaccine containing one or more proteins which elicits an antibody which recognizes a Mycoplasma hyopneumoniae antigen which lacks immunosuppressive activity. A particularly preferred intranasal vaccine includes the 74.5 kDa antigen of Mycoplasma hyopneumoniae. The 74.5 kDa antigen may be of recombinant origin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.